Berberine: Research
Overview
This page provides a curated overview of selected peer‑reviewed scientific studies examining berberine, a plant‑derived alkaloid found in several botanical species including Berberis plants. The goal of this page is to provide transparent access to commonly cited research in the scientific literature. The summaries below describe findings reported in published studies. They are presented for educational purposes as part of a clinician‑led review of the scientific literature.
Important Context for Readers
Scientific studies examine outcomes in defined populations under specific research conditions. Results reported in individual studies may not apply to all individuals, and findings should not be interpreted as guaranteed outcomes. This page summarizes selected research examining metabolic biomarkers and biological mechanisms studied in relation to berberine. It is not intended to provide medical advice, diagnosis, or treatment recommendations. This page is provided for educational purposes and does not include product recommendations or affiliate links.
Summary of Evidence
Across human clinical studies and meta‑analyses, berberine supplementation has been studied for its potential associations with changes in several metabolic biomarkers, including markers related to glucose metabolism, cholesterol, triglycerides, and body composition.
While results vary across study populations and trial designs, multiple randomized studies and meta‑analyses have reported changes in laboratory biomarkers associated with metabolic health. The studies listed below represent several frequently cited papers within the berberine literature. Many studies involve small sample sizes, short durations, specific populations (which may limit generalizability), and focus on biomarkers rather than long-term clinical outcomes.
Key Areas of Research
Mechanistic and Cellular Research
Evidence strength: Low (preclinical and experimental data)
1) Turner N, Li J, Gosby A, et al. Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I: A Mechanism for the Action of Berberine to Activate AMP-Activated Protein Kinase and Improve Insulin Action. Diabetes. 2008.
PMID: 18285556
DOI: https://doi.org/10.2337/db07-1552
Population: Experimental metabolic research models.
Design: Experimental laboratory research examining metabolic signaling pathways.
Key findings:
• Berberine has been reported to activate AMP‑activated protein kinase (AMPK), an energy‑sensing metabolic pathway
• AMPK signaling is involved in glucose uptake, fatty‑acid oxidation, and cellular energy balance.
Glucose and Insulin Metabolism
Evidence strength: Moderate to Strong.
Randomized trials and meta‑analyses have examined the relationship between berberine and biomarkers related to glucose metabolism, including fasting glucose, HbA1c, and insulin resistance markers.
2) Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008.
PMID: 18442638
DOI: https://doi.org/10.1016/j.metabol.2008.01.013
Population: Adults with type 2 diabetes (n=84)
Design: Randomized clinical trial evaluating berberine 500 mg three times daily over 3 months, including both monotherapy and combination-treatment phases.
Key findings:
• Reductions in HbA1c were reported (from ~9.5% to 7.5% in one cohort)
• Fasting glucose decreased from ~10.6 mmol/L to 6.9 mmol/L in the studied population
• Markers of insulin resistance (HOMA‑IR) decreased ~44.7%
• Triglycerides decreased from 1.13 to 0.89 mmol/L in the studied population
3) Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008.
PMID: 18397984
DOI: https://doi.org/10.1210/jc.2007-2404
Population: Adults with type 2 diabetes and dyslipidemia (n=116)
Design: Randomized clinical study evaluating metabolic biomarkers.
Key findings:
• HbA1c reduction of approximately 0.9–1.2% was reported
• Fasting glucose decreased significantly
• LDL cholesterol and triglycerides decreased during treatment
4) Zhao JV, Huang X, Zhang J, et al. Overall and sex-specific effect of berberine on glycemic and insulin-related traits: a systematic review and meta-analysis of randomized controlled trials. J Nutr. 2023.
PMID: 37598753
DOI: https://doi.org/10.1016/j.tjnut.2023.08.016
Population: Adults across randomized controlled trials evaluating glycemic and insulin-related outcomes, including individuals with type 2 diabetes and related metabolic conditions.
Design: Systematic review and meta-analysis of randomized controlled trials with subgroup and dose-response analyses.
Key findings:
• Reductions observed in fasting glucose, HbA1c, and insulin levels were reported across pooled analyses
• Improvements reported in insulin resistance markers in several included studies
• Dose-response relationships explored, suggesting greater effects at higher studied doses within trial ranges
• Subgroup analyses indicated variability based on population characteristics and study design
• Findings support associations with changes in glycemic biomarkers within the broader context of metabolic health
Metabolic disease
Several meta-analyses have evaluated berberine across multiple metabolic biomarkers, reflecting its investigation in populations with overlapping features of metabolic disease rather than isolated conditions.
5) Ye Y, Liu X, Wu N, et al. Efficacy and safety of berberine alone for several metabolic disorders: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021.
PMID: 33897554
DOI: https://doi.org/10.3389/fphar.2021.653887
Population: Adults with metabolic disorders including type 2 diabetes, dyslipidemia, obesity, and non-alcoholic fatty liver disease across pooled randomized trials.
Design: Systematic review and meta-analysis of randomized controlled trials.
Key findings:
• Reductions were reported in fasting glucose and HbA1c across pooled analyses
• Improvements in LDL cholesterol, triglycerides, and total cholesterol were observed
• Modest reductions reported in body weight and body mass index in some analyses
• Findings suggest multi-target effects across glucose and lipid metabolism pathways
• Heterogeneity noted across study designs, populations, and durations
6) Liu D, Zhao H, Zhang Y, et al. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol. 2025.
PMID: 40740996
DOI: https://doi.org/10.3389/fphar.2025.1572197
Population: Adults with metabolic syndrome and related metabolic disorders across pooled randomized controlled trials.
Design: Systematic review and meta-analysis of randomized placebo-controlled trials.
Key findings:
• HbA1c reductions generally reported in the range of ~0.5–1.0% across pooled trials
• Consistent decreases in fasting plasma glucose and insulin resistance markers (HOMA-IR)
• Improvements observed in lipid biomarkers including LDL-C and triglycerides
• Modest reductions in body weight and BMI reported in some subgroups
• Results support effects across multiple components of metabolic health rather than a single isolated endpoint
Lipid Metabolism and Cholesterol Biomarkers
Evidence strength: Moderate.
Several trials and pooled analyses have examined the relationship between berberine and lipid biomarkers including LDL cholesterol, triglycerides, and total cholesterol.
7) Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol‑lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004.
PMID: 15531889
DOI: https://doi.org/10.1038/nm1135
Population: Adults with hyperlipidemia.
Design: Clinical and mechanistic research examining lipid metabolism.
Key findings:
• Total cholesterol was reduced (~29%) in the studied population
• LDL‑C was reduced (~25%) in the studied population
• Triglycerides were reduced (~35%) in the studied population
8) Derosa G, D’Angelo A, Romano D, et al. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opinion on Pharmacotherapy. 2013.
PMID: 23441841
DOI: https://doi.org/10.1517/14712598.2013.776037
Population: Adults with low cardiovascular risk.
Design: Randomized clinical study evaluating the effects of berberine on metabolic and lipid biomarkers.
Key findings:
• Reductions reported in total cholesterol, LDL cholesterol and triglycerides in the studied population
• HDL cholesterol increased during the intervention period
• Lipid changes were observed during treatment and returned toward baseline during washout
• Findings support an association with changes in lipid biomarkers in a low cardiovascular risk population under study conditions
9) Dong H, Zhao Y, Zhao L, et al. The effects of berberine on blood lipids: a systemic review and meta‑analysis of randomized controlled trials. Planta Med. 2013.
PMID: 23512497
DOI: https://doi.org/10.1055/s-0032-1328321
Population: Pooled analysis of randomized trials involving adults with dyslipidemia or metabolic disorders.
Design: Meta-analysis of randomized clinical trials.
Key findings:
• LDL‑C reduction ~0.65 mmol/L reported across pooled analyses
• Triglycerides reduction ~0.50 mmol/L reported across pooled analyses
• Total cholesterol reduction ~0.61 mmol/L reported across pooled analyses
Liver Metabolism and Fatty Liver Research
Evidence strength: Low to Moderate.
10) Yan HM, Xia MF, Wang Y, et al. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLOS ONE. 2015.
PMID: 26252777
DOI: https://doi.org/10.1371/journal.pone.0134172
Population: Adults with non-alcoholic fatty liver disease participating in a clinical study.
Design: Randomized clinical study evaluating berberine combined with lifestyle intervention.
Key findings:
• Greater reductions in hepatic fat content were reported compared to lifestyle intervention alone
• Improvements reported in triglycerides, insulin resistance markers, body weight, and waist circumference were reported.
Gut microbiota
Evidence strength: Low.
11) Zhang, X., Zhao, Y., Xu, J. et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. 2015.
PMID: 26396057
DOI: https://doi.org/10.1038/srep14405
Population: Preclinical and translational animal microbiome models.
Design: Translational research examining interactions between berberine and gut microbiota.
Key findings: • Berberine altered gut microbial composition in experimental models
Educational Notice
These summaries are provided for educational purposes to review published scientific literature and should not be interpreted as medical advice, diagnosis, or treatment recommendations. Readers should consult qualified healthcare professionals for personal medical decisions.
FDA Disclaimer
These statements have not been evaluated by the U.S. Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.
FTC Affiliate Disclosure
Some pages on this website may contain affiliate links to products. If readers choose to purchase through those links, the site may receive a commission. Affiliate relationships do not influence the selection or discussion of scientific studies summarized on this reference page.